Alan Cassels
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alan Cassels has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Abbas Ali
Department of Family Medicine, McMaster University, Hamilton, Canada
1 shared publication - Anne Holbrook
McMaster University
1 shared publication - Barbara Farrell
University of Ottawa
1 shared publication - Barbara Mintzes
School of Pharmacy and Charles Perkins Centre, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia
1 shared publication - Cathy Risdon
Department of Family Medicine, McMaster University, David Braley Health Sciences Centre, 100 Main Street West, 5th floor, Hamilton, ON, L8P 1H6, Canada
1 shared publication - Daria O'Reilly
Department of Family Medicine, McMaster University, Hamilton, Canada
1 shared publication
Latest Publications
- Open Access
- 26 October 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-15
Team approach to polypharmacy evaluation and reduction: study protocol for a randomized controlled trial
Background: Polypharmacy in older adults can be associated with negative outcomes including falls, impaired cognition, reduced quality of life, and general and functional decline. It is not clear to what extent these are reversible if the number of medications is reduced. Primary care does not have a systematic approach for reducing inappropriate polypharmacy, and there are few, if any, approaches that account for the patient’s priorities and preferences. The primary objective of this study is to test the effect of TAPER (Team Approach to Polypharmacy Evaluation and Reduction), a structured operationalized clinical pathway focused on reducing inappropriate polypharmacy. TAPER integrates evidence tools for identifying potentially inappropriate medications, tapering, and monitoring guidance and explicit elicitation of patient priorities and preferences. We aim to determine the effect of TAPER on the number of medications (primary outcome) and health-related outcomes associated with polypharmacy in older adults.Methods: We designed a multi-center randomized controlled trial, with the lead implementation site in Hamilton, Ontario. Older adults aged 70 years or older who are on five or more medications will be eligible to participate. A total of 360 participants will be recruited. Participants will be assigned to either the control or intervention arm. The intervention involves a comprehensive multidisciplinary medication review by pharmacists and physicians in partnership with patients. This review will be focused on reducing medication burden, with the assumption that this will reduce the risks and harms of polypharmacy. The control group is a wait list, and control patients will be given appointments for the TAPER intervention at a date after the final outcome assessment. All patients will be followed up and outcomes measured in both groups at baseline and 6 months.Discussion: Our trial is unique in its design in that it aims to introduce an operationalized structured clinical pathway aimed to reduce polypharmacy in a primary care setting while at the same time recording patient’s goals and priorities for treatment.Trial registration: ClinicalTrials.govNCT02942927. First registered on October 24, 2016.
- 26 October 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-15
Open AccessTeam approach to polypharmacy evaluation and reduction: study protocol for a randomized controlled trial
Background: Polypharmacy in older adults can be associated with negative outcomes including falls, impaired cognition, reduced quality of life, and general and functional decline. It is not clear to what extent these are reversible if the number of medications is reduced. Primary care does not have a systematic approach for reducing inappropriate polypharmacy, and there are few, if any, approaches that account for the patient’s priorities and preferences. The primary objective of this study is to test the effect of TAPER (Team Approach to Polypharmacy Evaluation and Reduction), a structured operationalized clinical pathway focused on reducing inappropriate polypharmacy. TAPER integrates evidence tools for identifying potentially inappropriate medications, tapering, and monitoring guidance and explicit elicitation of patient priorities and preferences. We aim to determine the effect of TAPER on the number of medications (primary outcome) and health-related outcomes associated with polypharmacy in older adults.Methods: We designed a multi-center randomized controlled trial, with the lead implementation site in Hamilton, Ontario. Older adults aged 70 years or older who are on five or more medications will be eligible to participate. A total of 360 participants will be recruited. Participants will be assigned to either the control or intervention arm. The intervention involves a comprehensive multidisciplinary medication review by pharmacists and physicians in partnership with patients. This review will be focused on reducing medication burden, with the assumption that this will reduce the risks and harms of polypharmacy. The control group is a wait list, and control patients will be given appointments for the TAPER intervention at a date after the final outcome assessment. All patients will be followed up and outcomes measured in both groups at baseline and 6 months.Discussion: Our trial is unique in its design in that it aims to introduce an operationalized structured clinical pathway aimed to reduce polypharmacy in a primary care setting while at the same time recording patient’s goals and priorities for treatment.Trial registration: ClinicalTrials.govNCT02942927. First registered on October 24, 2016.
- 18 July 2019
- Published by CMA Impact Inc. in CMAJ Open
- Vol. 7 (3) , E472-E477
The impact of the introduction of a formulary into a large Canadian private drug plan: an interrupted time-series analysis
Most private drug plans in Canada do not use a formulary, which leads to suboptimal drug use. We studied the impact of the adoption of the public formulary by a large private health benefits plan in British Columbia. We studied the impact of a change by members of the BC Hospital Employees' Union to have their private drug plan mirror the public formulary as of June 2013. With data from Pacific Blue Cross, we conducted a before-and-after descriptive study using interrupted time-series analysis to study changes in covered drug costs and use for 18 months preceding and following the change. Our cohort averaged 66 000 plan members and dependents over our study period. Following the implementation of the formulary, the number of prescriptions covered by the plan declined by 0.46 prescriptions per member per month (95% confidence interval -0.50 to -0.42), a decline of 23.8% at 1 year. This decreased plan spending by $1.32 million over the 18 months after the coverage change, a 49.7% decline. The adoption of the public formulary by a large private drug plan in BC substantially reduced drug plan expenditures and the volume of prescriptions paid for by the plan. Overall, these results suggest that carefully designed formulary changes could substantially reduce spending by private-sector drug plans on drugs that have more cost-effective therapeutic alternatives.
- 18 July 2019
- Published by CMA Impact Inc. in CMAJ Open
- Vol. 7 (3) , E472-E477
The impact of the introduction of a formulary into a large Canadian private drug plan: an interrupted time-series analysis
Most private drug plans in Canada do not use a formulary, which leads to suboptimal drug use. We studied the impact of the adoption of the public formulary by a large private health benefits plan in British Columbia. We studied the impact of a change by members of the BC Hospital Employees' Union to have their private drug plan mirror the public formulary as of June 2013. With data from Pacific Blue Cross, we conducted a before-and-after descriptive study using interrupted time-series analysis to study changes in covered drug costs and use for 18 months preceding and following the change. Our cohort averaged 66 000 plan members and dependents over our study period. Following the implementation of the formulary, the number of prescriptions covered by the plan declined by 0.46 prescriptions per member per month (95% confidence interval -0.50 to -0.42), a decline of 23.8% at 1 year. This decreased plan spending by $1.32 million over the 18 months after the coverage change, a 49.7% decline. The adoption of the public formulary by a large private drug plan in BC substantially reduced drug plan expenditures and the volume of prescriptions paid for by the plan. Overall, these results suggest that carefully designed formulary changes could substantially reduce spending by private-sector drug plans on drugs that have more cost-effective therapeutic alternatives.
- 1 March 2018
- Published by Elsevier in Health Policy
- Vol. 122 (3) , 250-255
Reconciling a “pleasant exchange” with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care
- 1 March 2018
- Published by Elsevier in Health Policy
- Vol. 122 (3) , 250-255
Reconciling a “pleasant exchange” with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care
- Open Access
- 20 December 2016
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 24 (1) , 3-4
‘Can I stop even one of these pills?’ The development of a tool to make deprescribing easier
- 20 December 2016
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 24 (1) , 3-4
Open Access‘Can I stop even one of these pills?’ The development of a tool to make deprescribing easier
- 12 December 2011
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 183 (18) , E1359-E1360
"The first thing we do, let's kill all the actuaries"
My thesis is simple: Many decisions about where we will live and how we will be cared for as we grow old are not made by humans, they’re made by actuaries. And that’s why we need to slay them. If the first thought popping in your head is, “What the heck is an actuary?” don’t feel bad. No
- 12 December 2011
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 183 (18) , E1359-E1360
"The first thing we do, let's kill all the actuaries"
My thesis is simple: Many decisions about where we will live and how we will be cared for as we grow old are not made by humans, they’re made by actuaries. And that’s why we need to slay them. If the first thought popping in your head is, “What the heck is an actuary?” don’t feel bad. No
- 9 September 2008
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 179 (6) , 612
Grandma-forgets-to-take-her-meds disease
It's hard to develop a good conspiracy theory these days — that is, one that isn't too wacko. But here's one to test drive, one involving drug companies, retail drug stores and the investors, builders and operators of long-term care housing for the elderly. Clearly, there's a growing pile of cash
- 9 September 2008
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 179 (6) , 612
Grandma-forgets-to-take-her-meds disease
It's hard to develop a good conspiracy theory these days — that is, one that isn't too wacko. But here's one to test drive, one involving drug companies, retail drug stores and the investors, builders and operators of long-term care housing for the elderly. Clearly, there's a growing pile of cash
- Open Access
- 22 April 2008
- Vol. 2 (2) , e45-e48
How well do Canadian media outlets convey medical treatment information?
- 22 April 2008
- Vol. 2 (2) , e45-e48
Open AccessHow well do Canadian media outlets convey medical treatment information?
- Open Access
- 14 April 2007
- Vol. 1 (1) , e52-e54
The media-medicine mix: quality concerns in medical reporting
- 14 April 2007
- Vol. 1 (1) , e52-e54
Open AccessThe media-medicine mix: quality concerns in medical reporting